Research Author

Michelle T. Long

Novo Nordisk (Denmark)

ORCID OpenAlex profile

0Studies tracked

0Claims cite

0Videos use

Average study score: 88/100

Bibliography

Studies by this author

1 study attributed to Michelle T. Long on the platform. Click a card to read the full analysis.

Study

Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.

To evaluate the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stage 2 or 3.

High

Philip N. Newsome,Iris Kliers,Laura Østergaard+7 more

Read analysis